Theory Paper IDrNB Cardiology – Theory Notes
FONTAN SURGERY: INDICATIONS, CURRENT GUIDELINES & COMPLICATIONS
ITHE FONTAN PHYSIOLOGY AND INDICATIONS
- The Core Concept: The Fontan operation is not an anatomical cure; it is the final staged surgical palliation for patients born with a functionally univentricular heart (where biventricular repair is precluded by hypoplasia of one ventricle or non-septatable atrioventricular/ventriculoarterial connections).
- The Hemodynamic Physiology: Separates the pulmonary and systemic circulations in series so that the single functional ventricle pumps oxygenated blood exclusively into the systemic aorta, while all systemic venous return from the Superior Vena Cava (SVC) and Inferior Vena Cava (IVC) is routed directly into the pulmonary arteries (Total Cavopulmonary Connection [TCPC]) without a subpulmonary ventricular pump. Consequently, pulmonary blood flow is entirely passive, driven solely by the transpulmonary pressure gradient between Central Venous Pressure (CVP, typically 10 to 15 mmHg) and Systemic Atrial / Ventricular End-Diastolic Pressure (typically 5 to 8 mmHg).
- Primary Anatomical Indications:
Tricuspid Atresia.
Hypoplastic Left Heart Syndrome (HLHS).
Double Inlet Left Ventricle (DILV).
Unbalanced Atrioventricular Septal Defects (AVSD).
Pulmonary Atresia with Intact Ventricular Septum (PA-IVS) with severe RV hypoplasia or RV-dependent coronary circulation.
Complex Double Outlet Right Ventricle (DORV) with remote/non-routable VSD.
IITHE MODERN THREE-STAGE SURGICAL PATHWAY
- Physiological Rationale for Staging: A complete Fontan cannot be performed in a neonate because neonatal Pulmonary Vascular Resistance (PVR) is physiologically high (preventing passive cavopulmonary flow) and the single ventricle must gradually adapt from volume overload to normal preload.
- Stage 1 (Neonatal Period — First Weeks of Life): Optimizes balanced pulmonary and systemic blood flow while protecting the pulmonary vascular bed from overcirculation:
- For Decreased Pulmonary Flow (e.g., Tricuspid Atresia with PS/PA): Modified Blalock-Thomas-Taussig (mBTT) Shunt or transcatheter PDA stenting.
- For Unobstructed High Pulmonary Flow (e.g., DILV or Tricuspid Atresia without PS): Pulmonary Artery (PA) Banding to restrict pulmonary pressure and prevent PVOD.
- For Systemic Outflow Obstruction (HLHS): Norwood Procedure (reconstructing the neoaorta using the main PA + either a Sano RV-to-PA conduit or mBTT shunt + atrial septectomy).
- Stage 2 (4 to 6 Months of Age): Bidirectional Glenn (BDG) Shunt (superior cavopulmonary anastomosis) or Hemi-Fontan. Once PVR has fallen after infancy, the SVC is anastomosed end-to-side to the right pulmonary artery (and the Stage 1 shunt is taken down), routing upper-body venous return (approx. 50 percent of venous return in infants) passively to both lungs and unloading the single ventricle.
- Stage 3 (2 to 4 Years of Age / Weight 10 to 15 kg): Fontan Completion. The IVC (and hepatic venous return) is routed to the pulmonary artery via a Lateral Tunnel or Extracardiac Conduit, completing the Total Cavopulmonary Connection. (Routing hepatic venous blood containing hepatic factor to both lungs is also essential to prevent or reverse pulmonary arteriovenous malformations [PAVMs] that can develop after a Glenn shunt.)
IIICURRENT SURGICAL TECHNIQUES AND GUIDELINE STANDARDS (ESC 2020 / AHA 2019)
- The Extracardiac Conduit (ECC) vs. Lateral Tunnel (LT): Both forms of Total Cavopulmonary Connection (TCPC) have completely replaced the classical Atriopulmonary Connection (APC). The Extracardiac Conduit uses an 18 to 20 mm Gore-Tex (PTFE) tube outside the heart connecting the IVC to the right PA; it can be performed without aortic cross-clamping, preserves optimal laminar flow, leaves the entire atrium at low pressure, and minimizes sinus node injury and late atrial arrhythmias.
- The Conduit Fenestration (“Pop-Off Safety Valve”): A calibrated 4 mm communication created between the Fontan baffle/conduit and the pulmonary venous atrium. In the presence of post-operative PVR spikes, the fenestration allows controlled right-to-left shunting that decompresses systemic venous pressure (reducing pleural effusions) and maintains systemic ventricular preload and cardiac output at the expense of mild arterial desaturation (SpO2 88 to 92 percent).
| Stage / Parameter | Timing & Procedure | Key Hemodynamic / Exam Target |
|---|---|---|
| Stage 1 (Neonatal) | Norwood / mBTT Shunt / PA Band (0–1 month) | Unobstructed systemic outflow + controlled low-pressure pulmonary flow |
| Stage 2 (Cavopulmonary) | Bidirectional Glenn / Hemi-Fontan (4–6 months) | SVC to RPA; unloads single ventricle volume load after neonatal PVR falls |
| Stage 3 (Completion) | Extracardiac Conduit (18–20 mm) or Lateral Tunnel (2–4 years) | Ideal pre-Fontan hemodynamics: mPAP <15 mmHg, PVR <2–3 WU, VEDP <12 mmHg |
| Failing Fontan Criteria | Late decompensation on RHC | Fontan/CVP pressure >15–18 mmHg, cardiac index <2.0 L/min/m2, PLE, PB, or cirrhosis |
IVTHE “FAILING FONTAN”: MAJOR CARDIAC AND EXTRACARDIAC COMPLICATIONS
AExtracardiac Complications (Driven by Chronic Venous Hypertension [CVP 15 to 20 mmHg] & Lymphatic Congestion)
- Fontan-Associated Liver Disease (FALD): Universal time-dependent consequence of chronic non-pulsatile hepatic venous hypertension and low cardiac output, progressing from sinusoidal dilation to bridging fibrosis, cardiac cirrhosis, portal hypertension, and Hepatocellular Carcinoma (HCC).
- Protein-Losing Enteropathy (PLE): Occurs in 5 to 12 percent of survivors. Elevated mesenteric venous pressure and intestinal lymphangiectasia cause severe enteric loss of albumin, immunoglobulins, calcium, and lymphocytes—presenting with anasarca, ascites, chronic diarrhea, hypoalbuminemia, and elevated fecal alpha-1 antitrypsin.
- Plastic Bronchitis (PB): Decompression of pressurized thoracic duct lymph into the bronchial tree produces large rubbery, branching mucofibrinous airway casts, presenting with chronic cough, wheezing, cast expectoration, and life-threatening asphyxiation.
BCardiac and Vascular Complications
- Progressive Systemic Ventricular Dysfunction: Chronic preload deprivation, increased systemic arterial afterload, myocardial fibrosis, and atrioventricular valve regurgitation lead to systolic and diastolic failure (especially when a morphological Right Ventricle serves as the systemic chamber, as in HLHS).
- Atrial Tachyarrhythmias: Intra-Atrial Reentrant Tachycardia (IART) and Atrial Fibrillation occur in up to 50 percent of older APC Fontans. Loss of AV synchrony causes an immediate rise in atrial pressure and catastrophic drop in passive pulmonary flow; sustained IART is a medical emergency requiring prompt cardioversion.
- Thromboembolism: Sluggish, non-pulsatile cavopulmonary flow, dilated right atrium (in APC), prosthetic material, and hepatic coagulation factor abnormalities create a 10 to 20 percent lifetime risk of Fontan conduit/pulmonary artery thrombosis or paradoxical stroke across a fenestration.
VLONG-TERM MANAGEMENT AND GUIDELINE MANDATES (ESC 2020 ACHD / AHA 2019)
- Invasive Hemodynamic Evaluation (Class I): Cardiac catheterization must be performed at a low threshold in any Fontan patient developing unexplained edema, exercise deterioration, cyanosis, new arrhythmia, hemoptysis, PLE, or plastic bronchitis to identify treatable Fontan pathway/PA stenosis (where even a 1 to 2 mmHg gradient is hemodynamically significant and requires stenting), aortopulmonary/venovenous collaterals (requiring coil occlusion), or elevated PVR.
- Antithrombotic Therapy: Lifelong Oral Anticoagulation (Warfarin, target INR 2.0 to 3.0; Class I) is mandatory in patients with prior thromboembolism, atrial arrhythmias, right-to-left shunt/fenestration, or classical APC with atrial stasis; antiplatelet therapy or DOACs (studied in the UNIVERSE Trial) are used in low-risk uncomplicated ECC patients, while DOACs remain contraindicated in mechanical valves.
- Mandatory FALD Surveillance (Class I): Baseline and serial every 1-to-2-year liver evaluation using hepatic biochemical panels, Alpha-Fetoprotein (AFP), liver ultrasound / elastography (FibroScan), and hepatology co-management to screen for cirrhosis and HCC.
- Surgical Fontan Conversion and Transplantation: Patients with a failing classical Atriopulmonary Fontan and refractory atrial arrhythmias/thrombus with preserved ventricular function should undergo Surgical Fontan Conversion to an Extracardiac TCPC with Right Atrial Reduction and Cryo-Maze Ablation (plus epicardial dual-chamber pacemaker). Patients with end-stage ventricular failure, refractory PLE, or plastic bronchitis require Heart Transplantation (or Combined Heart-Liver Transplantation if advanced cirrhosis/HCC is present).
- Pregnancy Risk Stratification (2018 ESC Pregnancy / 2020 ESC ACHD Guidelines):
- Uncomplicated, Well-Functioning Fontan (mWHO Class III): High risk (40 to 50 percent miscarriage rate, prematurity, postpartum hemorrhage, and atrial arrhythmias), requiring management in an expert multidisciplinary ACHD center.
- Complicated or Failing Fontan (mWHO Class IV — Pregnancy Strictly Contraindicated, Class III): Pregnancy is contraindicated if the patient has resting SpO2 less than 85 percent, depressed systemic ventricular function, moderate-to-severe AV valve regurgitation, refractory arrhythmias, or Protein-Losing Enteropathy / Plastic Bronchitis.
Key references
- Baumgartner H, De Backer J, Babu-Narayan SV, et al.: 2020 ESC Guidelines for the management of adult congenital heart disease, European Heart Journal, 2020.
- Rychik J, Atz AM, Celermajer DS, et al.: Evaluation and Management of the Child and Adult With Fontan Circulation: A Scientific Statement From the American Heart Association, Circulation, 2019.
- Stout KK, Daniels CJ, Aboulhosn JA, et al.: 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease, Circulation, 2019. LAST REVIEWED: October 2026
meritmedscript.comDr. Sidhartha Mullapudi
